Search Results

You are looking at 171 - 180 of 814 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

isolated lung metastases that do not respond completely to 6 weeks of chemotherapy. The AREN0533 study was designed to improve event-free survival (EFS) from 75% to 85% for patients with incomplete lung nodule response by adding cyclophosphamide

Full access

Wells A. Messersmith

metachronous metastases, primary resection is preferred, with consideration of local therapy or neoadjuvant chemotherapy. The EORTC 40983 trial compared surgery alone with FOLFOX before and after surgery in patients with resectable liver metastases from CRC

Full access

Yi-Jen Chen

Over the past 30 years, the incidence of invasive anal carcinoma in the United States has increased at a rate of roughly 2% per year. 1 Most patients present with locoregionally confined disease; distant metastases often involving liver, lung, or

Full access

Jilma Patrick and Seema Ahsan Khan

present with de novo stage IV breast cancer. 1 Although systemic therapy is clearly the primary treatment for women with overt metastases, retrospective data published over the past decade have suggested that primary tumor resection (and possibly

Full access

Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee

primary (CK7+, CK20-, TTF1+). The patient's tumor was negative for both KRAS and epidermal growth factor receptor (EGFR)–activating mutations. PET/CT showed the FDG-avid mass in the right upper lobe of the lung, and metastases to the bone, liver, and

Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

summarized in this section. Whole-brain RT (WBRT) and stereotactic radiosurgery (SRS) for brain metastases are also discussed in this section. The abbreviations for RT are defined in the algorithm (see Table 1 , page1742). General Principles: Treatment

Full access

Paul B. Chapman

. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma . Lancet 1998 ; 351 : 1905 – 1910 . 12 Cascinelli N

Full access

Michael A. Gold

metastases—a Gynecologic Oncology Group study . Gynecol Oncol 1990 ; 38 : 425 – 430 . 6. Kim SH Choi BI Han JK . Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients . J Comput Assist Tomogr 1993 ; 17

Full access

be enrolled in this multicenter study. Primary Objective: Determine progression-free survival (PFS) [time frame: start of induction, osimertinib up to 22 months] Secondary Objectives: Determine time to appearance of new metastases [time frame: start

Full access

) Secondary Objectives: Time to appearance of new metastases, progression of target lesions, and progression of nontarget lesions (time frame: start of induction osimertinib to development of a new lesion, up to 22 months) Adverse events of osimertinib